Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr

JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

Allergan’s conclave on World Sight Day spotlights eyecare's crucial role in workplace

India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness

Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

Dr. Agarwal's Health Care raises US$80 mn from TPG and Temasek to expand network to 300 hospitals

The company has new projects in development in Mumbai, Punjab, central and northern India, among others

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved